eligibility_summary
Inclusion: ≥18, path-confirmed bladder urothelial carcinoma (T4N0 or T1–4N2–3), ECOG 0–2, Hgb ≥9, Plt ≥100, ANC ≥1500, CrCl ≥30, definitive local therapy candidate, contraception through 6 mo post-RT. Exclusion: prior pelvic RT, unradiatable distant mets, RT-limiting autoimmune dz, uncontrolled DM, G≥2 neuropathy/toxicity, active infection on IV antimicrobials, HBV/HCV/HIV, >10 mg prednisone/immunosupp., ILD/pneumonitis, prior transplant, active TB, pregnancy (neg test ≤6 wks).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Enfortumab vedotin (EV) plus radiation therapy. Drug type/mechanism: EV is an antibody–drug conjugate that targets Nectin‑4 on urothelial cancer cells, after binding and internalization, its MMAE payload (a microtubule inhibitor) is released, disrupting microtubules, causing G2/M arrest and apoptosis. Radiation mechanism: external-beam ionizing radiation induces tumor DNA damage (double-strand breaks), leading to cell death. Cells/pathways targeted: Nectin‑4–expressing bladder tumor cells, microtubule/cell-cycle machinery (via MMAE), DNA damage/repair pathways in irradiated tumor tissue (via radiation).